CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ÃÖÁøÁ¤
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : ·ù¸¶Æ¼½ºÁúȯ/·ù¸¶Æ¼½º°üÀý¿°/Àü½ÅÈ«¹Ý·çǪ½º/Åëdz
  • Á÷ À§: ±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
9 (±¹³»)KCI Àü½Å¼º È«¹Ý¼º ·çǪ½ºÀÇ Áø´Ü°ú Ä¡·á
8 (±¹¿Ü)SCI Serum Calprotectin as a Marker for Disease Activity and Severity in Adult-onset Still¡¯s Disease
7 (±¹¿Ü)SCI Circulating osteoprotegerin levels are elevated and correlated with antiphospholipid antibodies in patients with systemic lupus erythematosus
6 (±¹³»)KCI Cutaneous leg ulcer mimicking Pyoderma gangrenosum in patients with secondary antiphospholipid syndrome.
5 (±¹¿Ü)SCI Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice
4 (±¹¿Ü)SCI Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts
3 (±¹³»)SCIE Serum Amyloid A as a Useful Indicator of Disease Activity in Patients with Ankylosing Spondylitis
2 (±¹¿Ü)SCI Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts
1 (±¹³»)KCI Àü½ÅÈ«¹Ý·çǪ½º ȯÀÚ¿¡¼­ Ç÷û Osteoprotegerin Áõ°¡
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729